MedTrace Logo

SubCutaneous (SC) Versus Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients

NCT01222819 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2016-04-06

No results posted yet for this study

Summary

Granulocyte colony stimulating factor (G-CSF) is frequently used among patients with cancer including those with haematological malignancies.

Filgrastim is a recombinant human CSF whose biological activity is similar to that of endogenous G-CSF.

In the treatment of chemotherapy-induced neutropenia in patients with various types of cancer CSFs significantly reduced the time to neutrophil recovery and length of hospitalization.

Conditions

Interventions

DRUG

filgrastim

5 mcg/kg (rounded to 300 mcg or 480 mcg)

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Principal Investigators

  • Mical Paul, M.D. · Rabin Medical Center

  • Pia Raanani, M.D. · Rabin Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-12-31
Completion
2013-04-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01222819 on ClinicalTrials.gov